<DOC>
	<DOCNO>NCT02135887</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled multi-center phaseⅢstudy evaluate efficacy safety oxaliplatin-based chemotherapy plus MB-6 ( 320 mg/capsule , 6 capsule tid ) patient stage 3 colorectal cancer underwent surgical excision primary tumor .</brief_summary>
	<brief_title>A Trial MB-6 Reduction Neutropenia Induced Chemotherapy Patients With Stage III Colorectal Cancer .</brief_title>
	<detailed_description>The investigational new drug , MB-6 , propose clinical trial use adjuvant therapy metastatic colorectal cancer patient . All six extract use human long history , many literature report medicinal use either individually ingredient formulation . MB-6 may provide therapeutic benefit via inhibition tumor induction enhance efficacy chemotherapy colorectal cancer .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<criteria>1 . Men woman 20 year age old . 2 . Histologically cytologically confirm stage 3 colorectal adenocarcinoma . 3 . Complete resection primary tumor without gross microscopic evidence residual disease . 4 . No 8 week elapse time surgery recover effect . 5 . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) &lt; 2 time screen . 6 . Hematological function : ANC≥1500/mm3 , Hemoglobin ≥9.0 g/dL , Platelet count ≥100000/mm3 . 7 . Kidney function : Serum creatinine &lt; 2 mg/dL . 8 . Liver function : AST ≤3 time ULN , ALT ≤3 time ULN , Total Bilirubin ≤2 time ULN . 9 . Ability understand willingness sign write informed consent document accord institutional guideline . 10 . Men woman childbearing potential must agree employ adequate contraception study period . 1 . History second primary malignancy except adequately treat basal cell carcinoma skin carcinoma situ cervix . 2 . Systemic chemotherapy , immune therapy experimental approve antibodies/proteins ( e.g . bevacizumab ) administer surgery prior randomization . 3 . Concurrent treatment anticancer therapy . 4 . Radiotherapy ≤14 day prior randomization . 5 . Any unresolved toxicity &gt; CTC ( Common Toxicity Criteria ) grade 1 previous anticancer therapy ( include radiotherapy ) except haematological toxicity alopecia . 6 . Patients congestive heart failure , epilepsy , significant medical condition judge investigator . 7 . Contraindications FOLFOX chemotherapy : peripheral neuropathy NCI CTC &gt; 1 , liver failure , uncontrolled coronary heart disease , myocardial infarction within previous 6 month randomization . 8 . Patient childbearing potential evidently pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Stage III Colorectal Cancer</keyword>
	<keyword>Grade 4 Neutropenia</keyword>
	<keyword>MB-6</keyword>
</DOC>